2023
First-line Systemic Treatment Options for Metastatic Castration-Sensitive Prostate Cancer
Bin Riaz I, Naqvi S, He H, Asghar N, Siddiqi R, Liu H, Singh P, Childs D, Ravi P, Hussain S, Murad M, Boorjian S, Sweeney C, Van Allen E, Bryce A. First-line Systemic Treatment Options for Metastatic Castration-Sensitive Prostate Cancer. JAMA Oncology 2023, 9: 635-645. PMID: 36862387, PMCID: PMC9982744, DOI: 10.1001/jamaoncol.2022.7762.Peer-Reviewed Original ResearchMeSH KeywordsAgedAndrogen AntagonistsAndrogensCastrationHumansMaleMiddle AgedNetwork Meta-AnalysisProstatic NeoplasmsQuality of LifeConceptsMetastatic castration-sensitive prostate cancerCastration-sensitive prostate cancerAndrogen pathway inhibitorsSystemic treatment optionsProgression-free survivalOverall survivalTreatment optionsClinical trialsTriplet therapyProstate cancerFirst-line systemic treatment optionComparative effectivenessFirst-line treatment optionHigh-volume diseaseHigher adverse eventsImproved overall survivalLow-volume diseaseHealth-related qualityFuture clinical trialsDifferent treatment optionsHeterogeneous patient populationVolume of diseaseOutcomes of interestTriplet regimensEligible RCTs
2022
Quantifying absolute benefit for adjuvant treatment options in renal cell carcinoma: A living interactive systematic review and network meta-analysis
Riaz I, Sipra Q, Naqvi S, He H, Siddiqi R, Islam M, Asghar N, Ikram W, Xu W, Liu H, Singh P, Ho T, Bilen M, Zakharia Y, Bryce A, Murad M. Quantifying absolute benefit for adjuvant treatment options in renal cell carcinoma: A living interactive systematic review and network meta-analysis. Critical Reviews In Oncology/Hematology 2022, 175: 103706. PMID: 35537621, DOI: 10.1016/j.critrevonc.2022.103706.Peer-Reviewed Original ResearchConceptsRenal cell carcinomaAbsolute benefitCell carcinomaTreatment-related grade 3Adjuvant treatment optionsHigher adverse eventsDisease-free survivalRisk-adapted strategyDelays disease progressionLarger tumor sizeEvidence synthesis frameworkAdjuvant therapyAdjuvant treatmentOverall survivalAdverse eventsNodal positivityLeibovich scoreTumor sizeTreatment optionsDisease progressionRisk groupsGrade 3Current evidenceComparative effectivenessSystematic review
2021
Direct Oral Anticoagulants Compared With Dalteparin for Treatment of Cancer-Associated Thrombosis: A Living, Interactive Systematic Review and Network Meta-analysis
Riaz I, Fuentes H, Naqvi S, He H, Sipra Q, Tafur A, Padranos L, Wysokinski W, Marshall A, Vandvik P, Montori V, Bryce A, Liu H, Badgett R, Murad M, McBane R. Direct Oral Anticoagulants Compared With Dalteparin for Treatment of Cancer-Associated Thrombosis: A Living, Interactive Systematic Review and Network Meta-analysis. Mayo Clinic Proceedings 2021, 97: 308-324. PMID: 34172290, DOI: 10.1016/j.mayocp.2020.10.041.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, OralAnticoagulantsDalteparinHemorrhageHeparin, Low-Molecular-WeightHumansNeoplasmsNetwork Meta-AnalysisVenous ThromboembolismConceptsDirect oral anticoagulantsCancer-associated thrombosisTreatment of CATMajor bleedingSystematic reviewOral anticoagulantsRecurrent venous thromboembolism (VTE) eventsRelevant nonmajor bleedingUse of apixabanVenous thromboembolism eventsNetwork Meta-AnalysisStandard of careDifferent treatment optionsMixed treatment comparisonNonmajor bleedingThromboembolism eventsVTE recurrenceControlled TrialsWeight heparinTreatment optionsDalteparinHigh riskCurrent evidenceBleedingMeta-AnalysisA Living, Interactive Systematic Review and Network Meta-analysis of First-line Treatment of Metastatic Renal Cell Carcinoma
Riaz I, He H, Ryu A, Siddiqi R, Naqvi S, Yao Y, Husnain M, Narasimhulu D, Mathew J, Sipra Q, Vandvik P, Joseph R, Liu H, Wang Z, Herasevich V, Singh P, Hussain S, Ho T, Bryce A, Pagliaro L, Murad M, Costello B. A Living, Interactive Systematic Review and Network Meta-analysis of First-line Treatment of Metastatic Renal Cell Carcinoma. European Urology 2021, 80: 712-723. PMID: 33824031, DOI: 10.1016/j.eururo.2021.03.016.Peer-Reviewed Original ResearchMeSH KeywordsArtificial IntelligenceCarcinoma, Renal CellFemaleHumansKidney NeoplasmsMaleNetwork Meta-AnalysisNivolumabConceptsInteractive tableGraphical user interfaceUser interfaceUser-friendly formatAdvanced programmingDisplay resultsInteractive mannerInteractive reviewNetworkSearch strategyCurrent approachesSparse direct evidenceMetastatic renal cell carcinomaData extractionTableFirst-line treatmentProgrammingUntreated metastatic renal cell carcinomaFormatMultiple treatment optionsRenal cell carcinomaInherent biasesAdverse eventsComplete responseFramework